We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Enhancing Immune Cell Cytotoxicity and Persistence Insights Using Real-Time Cell Analysis

Enhancing Immune Cell Cytotoxicity and Persistence Insights Using Real-Time Cell Analysis
Credit: iStock

Cell therapies, from regenerative medicine to immunotherapy, are transforming the medical landscape with 75 already approved globally and over 2,000 in development.


As the field grows, there is a need for robust and reproducible potency assays to capture the full spectrum of effector cell activities, throughout process development and manufacturing, to ensure the safety of the end product.


Explore how cellular impedance assays using the latest real-time cell analysis (RTCA) platform can overcome the limitations of traditional endpoint assays in immunotherapy development, provide label-free, rapid and highly sensitive insights into cell potency, and support the requirements of 21 CFR Part 11.


Download this article to discover:

  • Challenges faced in measuring immune cell cytotoxicity
  • Potency assays available for cellular immunotherapies and the regulatory criteria they must meet
  • An real-time cell analysis platform that can facilitate significant time and cost savings


Brought to you by
Download the Article for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.